Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 3/20 | 0.59 |
| ▸ | TOP2A | P11388 | 1/20 | 0.51 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10552607 | 0.92 | STAT3 (0.58) | STAT3TOP2ATOP2BKMT2AHTT | |
| SCHEMBL1344823 | 0.90 | STAT3 (0.52) | STAT3TOP2ATOP2BKMT2AHTT | |
| SCHEMBL9686413 | 0.84 | STAT3 (0.47) | STAT3TOP2ATOP2BKMT2AHTT | |
| SCHEMBL500872 | 0.84 | KMT2A (0.63) | STAT3TOP2ATOP2BKMT2AHTT | |
| SCHEMBL8136260 | 0.83 | TOP2A (0.53) | STAT3TOP2ATOP2BKMT2AKDM4E | |
| SCHEMBL6756451 | 0.82 | STAT3 (0.61) | STAT3KMT2AHTTADRB2KDM4E | |
| SCHEMBL10668952 | 0.82 | STAT3 (0.61) | STAT3KMT2AHTTADRB2KDM4E | |
| SCHEMBL29895231 | 0.82 | STAT3 (0.61) | STAT3KMT2AHTTADRB2KDM4E | |
| SCHEMBL10672220 | 0.81 | STAT3 (0.59) | STAT3KMT2AHTTADRB2KDM4E | |
| SCHEMBL5258333 | 0.81 | STAT3 (0.62) | STAT3KMT2AHTTADRB2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1666477-B1 | 7-(4-SUBSTITUTED 3- CYCLOPROPYLAMINOMETHYL-1- PYRROLIDINYL) Q UINOLONECARBOXYLIC ACID DERIVATIVE | KYORIN SEIYAKU KK (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-8106072-B2 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090176824-A1 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative technical field | ASAHINA YOSHIKAZU | 2009-07-09 | — | — | US | disclosed |
| US-7514451-B2 | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20060281779-A1 | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| EP-1666477-A1 | 7-(4-SUBSTITUTED 3- CYCLOPROPYLAMINOMETHYL-1- PYRROLIDINYL) Q UINOLONECARBOXYLIC ACID DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-0288519-A4 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | — | 1992-04-15 | — | — | EP | disclosed |
| US-4965273-A | Certain 1-tertiary-butyl-naphthyridone carboxylic acid derivatives anti-bacterial agents | BRISTOL-MYERS COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| US-4954507-A | 1-tertiary-alkyl-substituted naphthyridine carboxylic acid antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| EP-0288519-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | Bristol-Myers Squibb Company (US) | 1988-11-02 | — | — | EP | disclosed |
| EP-0266576-A2 | 1-Tert-alkyl-substituted naphthyridine and quinoline carboxylic acids as antibacterial agents | Bristol-Myers Squibb Company (US) | 1988-05-11 | — | — | EP | disclosed |
| WO-1988002627-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1988-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176824-A1 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative technical field | CLPP, PRSS1, FOSB | STAT3 3715/4885TOP2A 138/4885TOP2B 219/4885 |
| US-20060281779-A1 | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative | RPS27L, RPS7, RPSA | STAT3 4345/4885TOP2A 171/4885TOP2B 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.